Liuvien

Liuvien
IOP elevation ≥ 10 mmHg from Baseline
Any surgical intervention for elevated intraocular pressure
Gain of ≥15 letters in BCVA (n (%))
Loss of ≥15 letters in BCVA (n (%))
Mean change from baseline in BCVA (SD)
Gain of ≥15 letters in BCVA (n (%))
Loss of ≥15 letters in BCVA (n (%))
Mean change from baseline in BCVA (SD)

Possible Questions to Ask your Doctor:

How does my diabetes affect DME?
How might DME impact my life?
Are there steps I can take to help slow the progression of DME?

Download a PDF with more questions

Please select one. Field is Required.
Which of the following describes you or your loved one? Having vision problems but not yet diagnosed with DME Recently diagnosed with DME but no treatment plan yet Diagnosed with DME and on a treatment plan Receiving treatment with ILUVIEN

By checking this box, I attest to the fact that I am 18 years of age or older and have read, understand, and agree to all of the Terms and Conditions , and that I have read and understand the Privacy Policy .

Hi [FIRST NAME]! I thought you might be interested in learning about ILUVIEN for DME. One injection delivers up to 3 years of continuous treatment for diabetic macular edema.

Here is a link to more information:
https://71b46f3a6a.nxcli.net/iluvien-diabetic-macular-edema/

I’ll follow up with you soon.
Sincerely, [YOUR NAME]
You can edit this message! Be sure to replace [FIRST NAME] with your recipient's name, and [YOUR NAME] in the message closing so they know it is from you.
This field is for validation purposes and should be left unchanged.
These highlights do not include all the information needed to use ILUVIEN® safely and effectively. See full prescribing information for ILUVIEN.
ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg
For Intravitreal Injection
Initial U.S. Approval: 1963
ILUVIEN contains a corticosteroid and is indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. ( 1 )
Non-bioerodable intravitreal implant containing 0.19 mg fluocinolone acetonide in a drug delivery system. ( 3 )
In controlled studies, the most common adverse reactions reported were cataract development and increases in intraocular pressure. ( 6.1 )
To report SUSPECTED ADVERSE REACTIONS, contact Alimera Sciences, Inc. at 1-844-445-8843 or FDA at
1‑800-FDA-1088 or
www.fda.gov/medwatch.
*Sections or subsections omitted from the full prescribing information are not listed.
ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg is indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.
For ophthalmic intravitreal injection.
The intravitreal injection procedure should be carried out under aseptic conditions, which include use of sterile gloves, a sterile drape, a sterile caliper, and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide should be given prior to the injection.
The injection procedure for ILUVIEN is as follows:
Following the injection, patients should be monitored for elevation in intraocular pressure and for endophthalmitis. Monitoring may consist of a check for perfusion of the optic nerve head immediately after the injection, tonometry within 30 minutes following the injection, and biomicroscopy between two and seven days following the injection. Patients should be instructed to report without delay any symptoms suggestive of endophthalmitis.
ILUVIEN is a non-bioerodable intravitreal implant in a drug delivery system containing
0.19 mg fluocinolone acetonide, designed to release fluocinolone acetonide at an initial rate of 0.25 μg/day and lasting 36 months.
4.1 Ocular or Periocular Infections
ILUVIEN is contraindicated in patients with active or suspected ocular or periocular infections including most viral disease of the cornea and conjunctiva including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections and fungal diseases.
ILUVIEN is contraindicated in patients with glaucoma, who have cup to disc ratios of greater than 0.8.
ILUVIEN is contraindicated in patients with known hypersensitivity to any components of this product.
5.1 Intravitreal Injection-related Effects
Intravitreal injections, including those with ILUVIEN , have been associated with endophthalmitis, eye inflammation, increased intraocular pressure, and retinal detachments. Patients should be monitored following the intravitreal injection [see Patient Counseling Information (17)] .
Use of corticosteroids including ILUVIEN may produce posterior subcapsular cataracts, increased intraocular pressure and glaucoma. Use of corticosteroids may enhance the establishment of secondary ocular infections due to bacteria, fungi, or viruses.
Corticosteroids are not recommended to be used in patients with a history of ocular herpes simplex because of the potential for reactivation of the viral infection.
Patients in whom the posterior capsule of the lens is absent or has a tear are at risk of implant migration into the anterior chamber.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Adverse reactions associated with ophthalmic steroids including ILUVIEN include cataract formation and subsequent cataract surgery, elevated intraocular pressure, which may be associated with optic nerve damage, visual acuity and field defects, secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera.
ILUVIEN was studied in two multicenter, randomized, sham-controlled, masked trials in which patients with diabetic macular edema (DME) were treated with either ILUVIEN (n=375) or sham (n=185).
Table 1 summarizes safety data available when the last subject completed the last 36 month follow up visit for the two primary ILUVIEN trials. In these trials, subjects were eligible for retreatment no earlier than 12 months after study entry. Over the three year follow up period, approximately 75% of the ILUVIEN treated subjects received only one ILUVIEN implant.
The most common ocular (study eye) and non-ocular adverse reactions are shown in Tables 1 and 2:
Table 1: Ocular Adverse Reactions Reported by ≥1% of Patients and
Non-ocular Adverse Reactions Reported by ≥5% of Patients
Table 2: Summary of Elevated IOP Related Adverse Reactions
Figure 1: Mean IOP during the study
At baseline, 235 of the 375 ILUVIEN subjects were phakic; 121 of 185 sham-controlled subjects were phakic. The incidence of cataract development in patients who had a phakic study eye was higher in the ILUVIEN group (82%) compared with Sham (50%). The median time of cataract being reported as an adverse event was approximately 12 months in the ILUVIEN group and 19 months in the Sham group. Among these patients, 80% of ILUVIEN subjects vs. 27% of sham-controlled subjects underwent cataract surgery, generally within the first 18 months (Median Month 15 for both ILUVIEN group and for Sham) of the studies.
The following reactions have been identified during post-marketing use of ILUVIEN in clinical practice. Because they are reported voluntarily estimates of frequency cannot be made. The reactions, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to ILUVIEN , or a combination of these factors, include reports of drug administration error and reports of the drug being ineffective.
There are no adequate and well-controlled studies of ILUVIEN in pregnant women. Animal reproduction studies have not been conducted with fluocinolone acetonide. Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. ILUVIEN should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Systemically administered corticosteroids are present in human milk and could suppress growth and interfere with endogenous corticosteroid production. The systemic concentration of fluocinolone acetonide following intravitreal treatment with ILUVIEN is low [see Clinical Pharmacology (12.3)]. It is not known whether intravitreal treatment with ILUVIEN could result in sufficient systemic absorption to produce detectable quantities in human milk. Exercise caution when ILUVIEN is administered to a nursing woman.
Safety and effectiveness of ILUVIEN in pediatric patients have not been established.
No overall differences in safety or effectiveness have been observed between elderly and younger patients.
ILUVIEN is a sterile non-bioerodable intravitreal implant containing 0.19 mg (190 mcg) fluocinolone acetonide in a 36-month sustained-release drug delivery system. ILUVIEN is designed to release fluocinolone acetonide at an initial rate of 0.25 μg/day. ILUVIEN is preloaded into a single-use applicator to facilitate injection of the implant directly into the vitreous. The drug substance is a synthetic corticosteroid, fluocinolone acetonide.
The chemical name for fluocinolone acetonide is (6α,11β,16α)-6,9-difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis-(oxy)]-pregna-1,4-diene-3,20-dione. Its chemical structure is:
MW 452.50; molecular formula C 24 H 30 F 206
Fluocinolone acetonide is a white or almost white, microcrystalline powder, practically insoluble in water, soluble in methanol, ethanol, chloroform and acetone, and sparingly soluble in ether.
Each ILUVIEN consists of a light brown 3.5mm x 0.37mm implant containing 0.19 mg of the active ingredient fluocinolone acetonide and the following inactive ingredients: polyimide tube, polyvinyl alcohol, silicone adhesive and water for injection.
Corticosteroids inhibit inflammatory responses to a variety of inciting agents including multiple inflammatory cytokines. They inhibit edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation.
Corticosteroids are thought to act by inhibition of phospholipase A2 via induction of inhibitory proteins collectively called lipocortins. It is postulated that these proteins control biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting release of the common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.
In a human pharmacokinetic study of ILUVIEN , fluocinolone acetonide concentrations in plasma were below the lower limit of quantitation of the assay (100 pg/mL) at all post-administration time points from Day 7 through Month 36 following intravitreal administration of a 0.2 mcg/day or 0.5 mcg/day fluocinolone acetonide insert.
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
Long-term animal studies have not been conducted to determine the carcinogenic potential or the effect on fertility of ILUVIEN .
Fluocinolone acetonide was not genotoxic in vitro in the Ames test (S. typhimurium and E. coli) and the mouse lymphoma TK assay, or in vivo in the mouse bone marrow micronucleus assay.
The efficacy of ILUVIEN was assessed in two three year, randomized (2:1, active: sham), multicenter, double-masked, parallel-groups studies that enrolled patients with diabetic macular edema (DME) that had previously been treated with laser photocoagulation.
The primary efficacy endpoint in both trials was the proportion of subjects in whom vision had improved by 15 letters or more from baseline after 24 months of follow-up.
a Study 1: ILUVIEN , N=190; Sham, N=95
b Study 2: ILUVIEN , N=186; Sham, N=90
Visual acuity outcomes by lens status (Phakic or Pseudophakic) at different visits are presented in Figure 2 and Figure 3. The occurrence of cataracts impacted visual acuity during the study. Patients who were pseudophakic at baseline achieved greater mean BCVA change from baseline at the Month 24 study visit.
Figure 2: Proportion of subjects with >=15 Letters Improvement from Baseline BCVA in the Study Eye
Study 1: Phakic Subjects
Proportion (%) of Subjects Gaining ≥15 Letters (ITT LOCF)
Study 1: Pseudophakic Subjects
Proportion (%) of Subjects Gaining ≥15 Letters (ITT LOCF)
Study 2: Phakic Subjects
Proportion (%) of Subjects Gaining ≥15 Letters (ITT LOCF)
Study 2: Pseudophakic Subjects
Proportion (%) of Subjects Gaining ≥15 Letters (ITT LOCF)
Figure 3: Mean BCVA Change from Baseline
Study 1: Phakic Subjects
Mean Change from Baseline in BCVA (ITT LOCF)
Study 1: Pseudophakic Subjects
Mean Change from Baseline in BCVA (ITT LOCF)
Study 2: Phakic Subjects
Mean Change from Baseline in BCVA (ITT LOCF)
Study 2: Pseudophakic Subjects
Mean Change from Baseline in BCVA (ITT LOCF)
The BCVA outcomes for the Pseudophakic and Phakic subgroups from Studies 1 and 2 at Month 24 are presented in Table 5.
Table 5: Visual Acuity outcomes at Month 24
(Subgroup for pooled data with LOCF)
a Pseudophakic: ILUVIEN , N=140; Sham, N=64
b Phakic: ILUVIEN , N=236; Sham, N=121
16 HOW SUPPLIED/STORAGE AND HANDLING
ILUVIEN ® (fluocinolone acetonide intravitreal implant) 0.19 mg is supplied in a sterile single use preloaded applicator with a 25-gauge needle, packaged in a tray sealed with a lid inside a carton.
Storage: Store at 15° – 30° C (59° – 86° F).
Advise patients that a cataract may occur after treatment with ILUVIEN . If this occurs, advise patients that their vision will decrease, and they will need an operation to remove the cataract and restore their vision.
Advise patients that they may develop increased intraocular pressure with ILUVIEN treatment, and the increased IOP may need to be managed with eye drops, or surgery.
Intravitreal Injection-related Effects
Advise patients that in the days following intravitreal injection of ILUVIEN , patients are at risk for potential complications including in particular, but not limited to, the development of endophthalmitis or elevated intraocular pressure.
Advise patients that if the eye becomes red, sensitive to light, painful, or develops a change in vision, they should seek immediate care from an ophthalmologist.
Inform patients that they may experience temporary visual blurring after receiving an intravitreal injection. Advise patients not to drive or use machines until this has been resolved.
Manufactured for:
Alimera Sciences, Inc.
6310 Town Square, Suite 400
Alpharetta, GA 30005
Indication: ILUVIEN ® (fluocinolone acetonide intravitreal implant) 0.19 mg is indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch , or call 1-800-FDA-1088.
This site is intended for US residents only. ILUVIEN is a registered trademark of Alimera Sciences, Inc. CONTINUOUS MICRODOSING and the CONTINUOUS MICRODOSING symbol are trademarks of Alimera Sciences, Inc. Copyright © 2022 Alimera Sciences, Inc. All rights reserved. 1-844-445-8843. US-ILV-MMM-0029
Learn about the benefits of ILUVIEN, inspiring patient stories, financial assistance and more. We will keep emails to a minimum and only send you relevant, useful information!
Don’t worry! We will not save any email addresses. This only sends a one-time email.

All

Select the section you want to search in

All
Consumer
Professional
Pill ID
Interactions
News
FDA Alerts
Approvals
Pipeline
Clinical Trials
Care Notes
Natural Products

Browse all medications:

a
b
c
d
e
f
g
h
i
j
k
l
m
n
o
p
q
r
s
t
u
v
w
x
y
z
0-9

Advanced Search

CSA Schedule*
Not a controlled drug
N/A

Approval History
Drug history at FDA

Ad Choices

We comply with the HONcode standard for trustworthy health information.

Copyright © 2000-2022 Drugs.com. All rights reserved.

Generic name: fluocinolone acetonide
Dosage form: implant
Drug class: Ophthalmic steroids
Medically reviewed by Drugs.com. Last updated on Jan 1, 2022.
ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg is indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.
For ophthalmic intravitreal injection.
The intravitreal injection procedure should be carried out under aseptic conditions, which include use of sterile gloves, a sterile drape, a sterile caliper, and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide should be given prior to the injection.
The injection procedure for ILUVIEN is as follows:

Following the injection, patients should be monitored for elevation in intraocular pressure and for endophthalmitis. Monitoring may consist of a check for perfusion of the optic nerve head immediately after the injection, tonometry within 30 minutes following the injection, and biomicroscopy between two and seven days following the injection. Patients should be instructed to report without delay any symptoms suggestive of endophthalmitis.
ILUVIEN is a non-bioerodable intravitreal implant in a drug delivery system containing 0.19 mg fluocinolone acetonide, designed to release fluocinolone acetonide at an initial rate of 0.25 μg/day and lasting 36 months.
ILUVIEN is contraindicated in patients with active or suspected ocular or periocular infections including most viral disease of the cornea and conjunctiva including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections and fungal diseases.
ILUVIEN is contraindicated in patients with glaucoma, who have cup to disc ratios of greater than 0.8.
ILUVIEN is contraindicated in patients with known hypersensitivity to any components of this product.
Intravitreal injections, including those with ILUVIEN , have been associated with endophthalmitis, eye inflammation, increased intraocular pressure, and retinal detachments. Patients should be monitored following the intravitreal injection [see Patient Counseling Information (17) ] .
Use of corticosteroids including ILUVIEN may produce posterior subcapsular cataracts, increased intraocular pressure and glaucoma.
Use of corticosteroids may enhance the establishment of secondary ocular infections due to bacteria, fungi, or viruses.
Corticosteroids are not recommended to be used in patients with a history of ocular herpes simplex because of the potential for reactivation of the viral infection.
Patients in whom the posterior capsule of the lens is absent or
Muffet Undertale Porn
Masturbation Comic
Best Ass Yoga Pants

Liuvien

Report Page